Janssen Phase 3 HIV Vaccine Study Halted Due to Lack of Efficacy

Janssen has decided to discontinue the phase 3 Mosaico study evaluating the company’s investigational HIV vaccine regimen because the regimen was not effective in preventing HIV infection compared to placebo.

The study evaluated a “mosaic” vaccine based on genetic material from multiple HIV strains, which is intended to trigger a broader immune response compared with other vaccines.

The investigational vaccine regimen was administered during four visits within one year along with a mix of soluble proteins given during the third and fourth visits.

Although the study is being discontinued, “further analyses of the data are underway,” Janssen said.